| abstract |
The present invention relates to (20S) -1α-hydroxy-2α-methyl-19-nor-vitamin D 3 and (20S) -1α-hydroxy-2β-methyl-19-nor-vitamin D 3 , and pharmaceuticals thereof. Disclose use. These compounds show significant activity in inhibiting the proliferation of undifferentiated cells and inducing their differentiation into monocytes, and therefore as anticancer agents and skin diseases such as psoriasis, as well as wrinkles, sagging skin, dry skin and non-skins. Obviously, it can be used to treat skin conditions such as sufficient sebum secretion. These compounds also have very pronounced calcemic activity and can therefore be used to treat human immune disorders as well as metabolic bone diseases such as osteoporosis. |